Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 12/20 | 0.85 |
| ▸ | KDR | P35968 | 8/20 | 0.85 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.85 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.85 |
| ▸ | KIT | P10721 | 4/20 | 0.85 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.85 |
| ▸ | RET | P07949 | 3/20 | 0.85 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.85 |
| ▸ | FLT1 | P17948 | 3/20 | 0.85 |
| ▸ | FLT4 | P35916 | 3/20 | 0.85 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.85 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.85 |
| ▸ | ABL1 | P00519 | 3/20 | 0.85 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.85 |
| ▸ | STK10 | O94804 | 2/20 | 0.85 |
| ▸ | BCR | P11274 | 2/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.85 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.85 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.85 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248140 | 0.95 | FGFR4 (0.87) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL1895983 | 0.93 | FGFR4 (0.81) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL1895134 | 0.93 | FGFR4 (0.73) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL1889234 | 0.93 | FGFR4 (0.83) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL1248296 | 0.93 | FGFR4 (0.83) | FGFR4KDRFGFR1PDGFRAKIT | |
| Lenvatinib SCHEMBL29372021 | 0.92 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRAKIT | |
| Lenvatinib SCHEMBL29349806 | 0.92 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRAKIT | |
| Lenvatinib SCHEMBL864638 | 0.92 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL1895356 | 0.91 | FGFR4 (0.81) | FGFR4KDRFGFR1PDGFRAKIT | |
| SCHEMBL1897200 | 0.91 | KDR (0.70) | FGFR4KDRFGFR1PDGFRAKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2700403-B1 | THERAPEUTIC AGENT FOR TUMOR | EISAI R&D MAN CO LTD (JP) | 2015-11-25 | — | — | EP | claimed |
| EP-2036557-B1 | ANTITUMOR AGENT FOR THYROID CANCER | EISAI R&D MAN CO LTD (JP) | 2015-10-21 | — | — | EP | claimed |
| US-9012458-B2 | Antitumor agent using compounds having kinase inhibitory effect in combination | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-21 | — | — | US | claimed |
| US-9006240-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-14 | — | — | US | claimed |
| US-8969344-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-03 | — | — | US | claimed |
| US-8962650-B2 | Therapeutic agent for tumor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-24 | — | — | US | claimed |
| EP-2119707-B1 | COMPOSITION FOR TREATMENT OF UNDIFFERENTIATED-TYPE OF GASTRIC CANCER | EISAI R&D MAN CO LTD (JP) | 2015-01-14 | — | — | EP | claimed |
| EP-2700403-A1 | THERAPEUTIC AGENT FOR TUMOR | Eisai R&D Management Co., Ltd. (JP) | 2014-02-26 | — | — | EP | claimed |
| US-20140031384-A1 | THERAPEUTIC AGENT FOR TUMOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-01-30 | — | — | US | claimed |
| US-20130123274-A1 | Antitumor Agent Using Compounds Having Kinase Inhibitory Effect in Combination | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-16 | — | — | US | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| EP-1415987-B1 | NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS | EISAI R&D MAN CO LTD (JP) | 2007-02-28 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| EP-1604665-A1 | C-KIT KINASE INHIBITOR | Eisai Co., Ltd. (JP) | 2005-12-14 | — | — | EP | claimed |
| US-20040253205-A1 | c-Kit kinase inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-16 | — | — | US | claimed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | claimed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | FGFR4 682/4885KDR 22/4885FGFR1 165/4885 |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | FGFR4 49/4885KDR 2/4885FGFR1 30/4885 |
| US-20140031384-A1 | THERAPEUTIC AGENT FOR TUMOR | KRAS, TP53, HRAS | FGFR4 1419/4885KDR 1270/4885FGFR1 183/4885 |
| US-20130123274-A1 | Antitumor Agent Using Compounds Having Kinase Inhibitory Effect in Combination | MAP3K8, MAP3K20, MAP3K7 | FGFR4 1191/4885KDR 531/4885FGFR1 788/4885 |
| US-20040253205-A1 | c-Kit kinase inhibitor | KIT, MASTL, TNNI3K | FGFR4 2248/4885KDR 368/4885FGFR1 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.